- Home
- INMB vs CRVO Comparison
INMB vs CRVO Comparison
Compare INMB & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | CRVO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 35.9M |
| IPO Year | 2018 | 2011 |
Fundamental Metrics
Financial Performance| Metric | INMB | CRVO |
|---|---|---|
| Price | $1.21 | $2.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.40 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 471.5K | 61.4K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,000.00 | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $2.79 |
| 52 Week High | $11.64 | $13.13 |
Technical Indicators
Market Signals| Indicator | INMB | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 23.02 |
| Support Level | $1.15 | N/A |
| Resistance Level | $1.52 | $4.27 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 5.79 | 8.03 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.